208 related articles for article (PubMed ID: 33564618)
1. Cyclodextrin nanosponge for the GSH-mediated delivery of Resveratrol in human cancer cells.
Palminteri M; Dhakar NK; Ferraresi A; Caldera F; Vidoni C; Trotta F; Isidoro C
Nanotheranostics; 2021; 5(2):197-212. PubMed ID: 33564618
[TBL] [Abstract][Full Text] [Related]
2. Glutathione-responsive cyclodextrin-nanosponges as drug delivery systems for doxorubicin: Evaluation of toxicity and transport mechanisms in the liver.
Daga M; de Graaf IAM; Argenziano M; Barranco ASM; Loeck M; Al-Adwi Y; Cucci MA; Caldera F; Trotta F; Barrera G; Casini A; Cavalli R; Pizzimenti S
Toxicol In Vitro; 2020 Jun; 65():104800. PubMed ID: 32084521
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of solubility enhancement, antioxidant activity, and cytotoxicity studies of kynurenic acid loaded cyclodextrin nanosponge.
Dhakar NK; Caldera F; Bessone F; Cecone C; Pedrazzo AR; Cavalli R; Dianzani C; Trotta F
Carbohydr Polym; 2019 Nov; 224():115168. PubMed ID: 31472867
[TBL] [Abstract][Full Text] [Related]
4. Biological Effect Evaluation of Glutathione-Responsive Cyclodextrin-Based Nanosponges: 2D and 3D Studies.
Argenziano M; Foglietta F; Canaparo R; Spagnolo R; Della Pepa C; Caldera F; Trotta F; Serpe L; Cavalli R
Molecules; 2020 Jun; 25(12):. PubMed ID: 32560204
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Solubility, Cytotoxicity and Photostability Studies of Resveratrol and Oxyresveratrol Loaded Nanosponges.
Dhakar NK; Matencio A; Caldera F; Argenziano M; Cavalli R; Dianzani C; Zanetti M; López-Nicolás JM; Trotta F
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31635183
[TBL] [Abstract][Full Text] [Related]
6. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study.
Ansari KA; Vavia PR; Trotta F; Cavalli R
AAPS PharmSciTech; 2011 Mar; 12(1):279-86. PubMed ID: 21240574
[TBL] [Abstract][Full Text] [Related]
7. Ester-Based Hydrophilic Cyclodextrin Nanosponges for Topical Ocular Drug Delivery.
Hayiyana Z; Choonara YE; Makgotloe A; du Toit LC; Kumar P; Pillay V
Curr Pharm Des; 2016; 22(46):6988-6997. PubMed ID: 27981908
[TBL] [Abstract][Full Text] [Related]
8. GSH-responsive poly-resveratrol based nanoparticles for effective drug delivery and reversing multidrug resistance.
Liping Y; Jian H; Zhenchao T; Yan Z; Jing Y; Yangyang Z; Jing G; Liting Q
Drug Deliv; 2022 Dec; 29(1):229-237. PubMed ID: 35001781
[TBL] [Abstract][Full Text] [Related]
9. Pyromellitic dianhydride crosslinked cyclodextrin nanosponges for curcumin controlled release; formulation, physicochemical characterization and cytotoxicity investigations.
Rafati N; Zarrabi A; Caldera F; Trotta F; Ghias N
J Microencapsul; 2019 Dec; 36(8):715-727. PubMed ID: 31530203
[No Abstract] [Full Text] [Related]
10. GSH-targeted nanosponges increase doxorubicin-induced toxicity "in vitro" and "in vivo" in cancer cells with high antioxidant defenses.
Daga M; Ullio C; Argenziano M; Dianzani C; Cavalli R; Trotta F; Ferretti C; Zara GP; Gigliotti CL; Ciamporcero ES; Pettazzoni P; Corti D; Pizzimenti S; Barrera G
Free Radic Biol Med; 2016 Aug; 97():24-37. PubMed ID: 27184956
[TBL] [Abstract][Full Text] [Related]
11. Improving the solubility and in vitro cytotoxicity (anticancer activity) of ferulic acid by loading it into cyclodextrin nanosponges.
Rezaei A; Varshosaz J; Fesharaki M; Farhang A; Jafari SM
Int J Nanomedicine; 2019; 14():4589-4599. PubMed ID: 31296988
[No Abstract] [Full Text] [Related]
12. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
13. Cyclodextrin based nanosponge of norfloxacin: Intestinal permeation enhancement and improved antibacterial activity.
Mendes C; Meirelles GC; Barp CG; Assreuy J; Silva MAS; Ponchel G
Carbohydr Polym; 2018 Sep; 195():586-592. PubMed ID: 29805015
[TBL] [Abstract][Full Text] [Related]
14. Cyclodextrin-based nanosponge for improvement of solubility and oral bioavailability of Ellagic acid.
Mady FM; Ibrahim SR
Pak J Pharm Sci; 2018 Sep; 31(5(Supplementary)):2069-2076. PubMed ID: 30393214
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of exemestane into ternary nanosponge system for enhanced anti-tumor potential in breast cancer.
Mane PT; Wakure BS; Wakte PS
Pharm Dev Technol; 2023 Dec; 28(10):1000-1015. PubMed ID: 37961995
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of microparticles of β-cyclodextrin/glutathione and chitosan/glutathione obtained by spray-drying.
Webber V; de Siqueira Ferreira D; Barreto PLM; Weiss-Angeli V; Vanderlinde R
Food Res Int; 2018 Mar; 105():432-439. PubMed ID: 29433233
[TBL] [Abstract][Full Text] [Related]
17. Enhancement in the therapeutic potential of lapatinib ditosylate against breast cancer by the use of β-cyclodextrin based ternary nanosponge system.
Tanaji Mane P; Sopanrao Wakure B; Shridhar Wakte P
Int J Pharm; 2023 Jul; 642():123210. PubMed ID: 37433350
[TBL] [Abstract][Full Text] [Related]
18. Evolution of Cyclodextrin Nanosponges.
Caldera F; Tannous M; Cavalli R; Zanetti M; Trotta F
Int J Pharm; 2017 Oct; 531(2):470-479. PubMed ID: 28645630
[TBL] [Abstract][Full Text] [Related]
19. Solubility and dissolution rate enhancement of ibuprofen by cyclodextrin based carbonate nanosponges.
Shoaib QU; Latif S; Ijaz QA; Afzal H; Siddique MI; Hussain A; Arshad MS; Bukhari NI; Abbas N
Pak J Pharm Sci; 2021 May; 34(3(Supplementary)):1045-1055. PubMed ID: 34602431
[TBL] [Abstract][Full Text] [Related]
20. Nanosponge Carriers- An Archetype Swing in Cancer Therapy: A Comprehensive Review.
Osmani RA; Hani U; Bhosale RR; Kulkarni PK; Shanmuganathan S
Curr Drug Targets; 2017; 18(1):108-118. PubMed ID: 26424399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
